回顾性分析肺癌患者和非肺癌患者的异常糖链糖蛋白检测数据，探讨异常糖链糖蛋白不同截断值排查肺癌的效能。

采用凝聚素亲和法检测我院呼吸内科经治的176例肺癌患者和113例非肺癌患者的异常糖链糖蛋白水平，对所得两组患者的异常糖链糖蛋白数据进行统计学分析。

肺癌患者异常糖链糖蛋白水平高于非肺癌患者(P＝0.002)。血清TAP排查肺癌的曲线下面积(AUC)为0.622(95%CI：0.554-0.689，P<0.001)。肺癌患者异常糖链糖蛋白理想截断值是170 μm²。截断值(170 μm²)和截断值(≤121 μm²、121～225 μm²、≥225 μm²)分别应用于肺癌组、非肺癌组及肺癌组+非肺癌组，结果发现这两种截断值排查肺癌的效能不同，前者显示三组间存在显著性差异(P＝0.006)，而后者则显示三组之间并无明显差别(P＝0.577)。

异常糖链糖蛋白不同截断值排查肺癌的效能不同，将它单独应用于肺癌领域，其效能是比较低的。

To study the levels of tumor abnormal protein (TAP) in the patients with lung cancer in order to explore their efficacies in diagnosing lung cancer.

A total of 176 patients with lung cancer and 113 patients with non-lung cancer who were hospitalized in the Department of Respiratory and Critical Care Medicine, Tangdu Hospital, Airforce Military Medical University, Xi′an, China, were studied. Their levels of TAP were measured with the agglutinin affinity method. Then the TAP data were analyzed by statistical analysis.

The levels of TAP were higher in the patients with lung cancer than in the patients with non-lung cancer (P=0.002). The area under curve (AUC) of the serum TAP for lung cancer screening was 0.622 (95%CI: 0.554-0.689, P<0.001). When the cutoff value of TAP was 170 μm^2, the efficacies of sensitivity and specificity were best (P<0.05). Then the cutoff value 170 μm² and the cutoff values ≤121 μm^2, 121-225 μm^2, and ≥225 μm² were applied to the lung cancer group, non-lung cancer group and lung cancer group+ non-lung cancer group, respectively. It was found that the two groups of cutoff values were different in the screening efficacy of lung cancer. The former showed a significant difference between the three groups (P=0.006), while the latter showed no significant difference between the three groups (P=0.577).

Different cutoff values of TAP show different efficacies in lung cancer screening. If it is applied to the field of lung cancer alone, its efficacy is relatively low.